CIP2A and leukemia: In our previous studies, we demonstrated that bortezomib, a proteasome inhibitor, induced apoptosis via proteasome-independent inhibition of CIP2A in TNBC cells [13], hepatocellular carcinoma cells [41], leukemia cells [34] and head and neck cancer cells [40].